RUMORED BUZZ ON ABBV-744 FOR SMALL CELL LUNG CANCER RESEARCH

In Section C, members will receive ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment till disease progression or even the contributors are unable to tolerate the study drugs.- "Our study revealed the crucial role with the KLF16/MYC regulatory axis in modulating tumor expansion